Cargando…

Effect of Tamoxifen on the Management of Dopamine Agonist-Resistant Prolactinomas: A Systematic Review

The management of dopamine agonist (DA)-resistant prolactinomas unresponsive to second and third-line treatment is challenging and requires alternative medical therapy. The presence of estrogen receptors on pituitary tumors, and the variable behavior of pituitary tumors in the presence of estrogen,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bazuhair, Tuqa, Aleid, Bakhitah, Almalki, Mussa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2023
Materias:	Endocrinology/Diabetes/Metabolism
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10029104/ https://www.ncbi.nlm.nih.gov/pubmed/36950000 http://dx.doi.org/10.7759/cureus.35171

Ejemplares similares

The Mechanism and Pathways of Dopamine and Dopamine Agonists in Prolactinomas
por: Liu, Xiaoshuang, et al.
Publicado: (2019)

Prolactinoma: Clinical Characteristics, Management and Outcome
por: Irfan, Hira, et al.
Publicado: (2022)

Managing Prolactinomas during Pregnancy
por: Almalki, Mussa Hussain, et al.
Publicado: (2015)

Case Report: Temozolomide Treatment of Refractory Prolactinoma Resistant to Dopamine Agonists
por: Tang, Hao, et al.
Publicado: (2021)

Neuropsychiatric Effects in Patients With Invasive Prolactinomas Treated With Cabergoline
por: Calva-González, Metztli, et al.
Publicado: (2023)

Prolactinomas Resistant to Treatment With Dopamine Agonists: Long-Term Follow-Up of Six Cases
por: Gonzaga, Maria de Fátima de Magalhães, et al.
Publicado: (2018)

Applying Telemedicine Technology in Treating Prolactinomas: A Case Report
por: Khalil, Hiba, et al.
Publicado: (2020)

Prolactinomas in Moroccan Population: Clinical, Paraclinical, Therapeutic, and Evolutionary Aspects
por: Elazime, Zineb, et al.
Publicado: (2022)

A Coexisting Pilocytic Astrocytoma and a Prolactinoma: A Case Report of Collision Tumors and Literature Review
por: Malli, Antonia, et al.
Publicado: (2019)

Gender Disparities in Prolactinomas: Unravelling Clinical Patterns, Metabolic Variations, and Treatment Responses
por: Baba, Mohammad Salem, et al.
Publicado: (2023)

Immune Checkpoint Inhibitor-Induced Endocrine Adverse Events in Cancer Patients at a Tertiary Care Center in Saudi Arabia
por: Alqahtani, Ali, et al.
Publicado: (2023)

Puberty Induction in Adolescent Males: Current Practice
por: Alenazi, Mohammed S, et al.
Publicado: (2022)

Is prolactin receptor signaling a target in dopamine-resistant prolactinomas?
por: Ferraris, Jimena
Publicado: (2023)

Predictors of dopamine agonist resistance in prolactinoma patients
por: Vermeulen, Elle, et al.
Publicado: (2020)

Glycemic Control for Type 2 Diabetes Mellitus Patients: A Systematic Review
por: Bin Rakhis, Saud A, et al.
Publicado: (2022)

Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Cardiovascular Risk Management in Patients With Type 2 Diabetes Mellitus: A Systematic Review
por: Parab, Panah, et al.
Publicado: (2023)

Experience with Dopamine Agonists in the Treatment of Prolactinomas
por: Barabash, Nadiya Ye., et al.
Publicado: (2022)

Prevalence of Depression Among Patients With Type 2 Diabetes at King Abdullah Medical City
por: Aljohani, Wasayf, et al.
Publicado: (2021)

Role of Glucagon-Like Peptide-1 Receptor Agonists in the Management of Non-Alcoholic Steatohepatitis: A Clinical Review Article
por: Ghazanfar, Haider, et al.
Publicado: (2021)

Role of Glucagon-Like Peptide-1 Receptor Agonists on the Weight Loss of Individuals With Type 2 Diabetes: A Systematic Review
por: Irfan, Huma, et al.
Publicado: (2023)

Insights From the Current Practice of Pneumococcal Disease Prevention for Diabetic Patients in Saudi Arabia
por: Al-Dahash, Raed, et al.
Publicado: (2022)

Dopamine agonist therapy for prolactinomas: do we need to rethink the place of surgery in prolactinoma management?
por: De Sousa, Sunita M C
Publicado: (2022)

Immunohistochemical Expression of Ki-67, Dopamine D1 and Dopamine D2 Receptors in Meningiomas in a Tertiary Institution in Mexico
por: Rodríguez-Hernández, Luis A, et al.
Publicado: (2023)

Dopamine agonist resistant prolactinomas: any alternative medical treatment?
por: Souteiro, P., et al.
Publicado: (2019)

Clinical Management of Nonalcoholic Steatohepatitis (NASH) With the Use of Thiazolidinediones and the Additive Effect of Thiazolidinediones and a GLP-1 Agonist: Case Series
por: Rojas Ortiz, Valentina, et al.
Publicado: (2021)

Metabolic Effects of Ketogenic Diets and Their Utilization in Obesity Management: A Systematic Review
por: Malhotra, Vani, et al.
Publicado: (2023)

Does Insufficient Sleep Increase the Risk of Developing Insulin Resistance: A Systematic Review
por: Singh, Trisha, et al.
Publicado: (2022)

A Systematic Review: Does Insulin Resistance Affect the Risk and Survival Outcome of Breast Cancer in Women?
por: Srinivasan, Mirra, et al.
Publicado: (2022)

Metabolic effects of dopamine agonists in patients with prolactinomas: a systematic review and meta-analysis
por: Byberg, Sarah, et al.
Publicado: (2019)

The recurrence of prolactinoma after withdrawal of dopamine agonist: a systematic review and meta-analysis
por: Zou, Yunzhi, et al.
Publicado: (2021)

Cabergoline Treatment in Invasive Giant Prolactinoma
por: Alsubaie, Sadeem, et al.
Publicado: (2014)

PMON169 D2R Expression in Dopamine-Agonist Resistant Prolactinomas
por: Levine, Alice, et al.
Publicado: (2022)

Probiotics and Their Role in the Management of Type 2 Diabetes Mellitus (Short-Term Versus Long-Term Effect): A Systematic Review and Meta-Analysis
por: Ayesha, Ismat E, et al.
Publicado: (2023)

Pituitary surgery for small prolactinomas as an alternative to treatment with dopamine agonists
por: Babey, Muriel, et al.
Publicado: (2010)

Reducing the Number of Unnecessary Thyroid Nodule Biopsies With the American College of Radiology (ACR) Thyroid Imaging Reporting and Data System (TI-RADS)
por: Abou Shaar, Bader, et al.
Publicado: (2022)

Weight Loss of Over 100 lbs in a Patient of Prader-Willi Syndrome Treated With Glucagon-Like Peptide-1 (GLP-1) Agonists
por: Ahmed, Sana, et al.
Publicado: (2023)

Risk of Mucormycosis in Diabetes Mellitus: A Systematic Review
por: Khanna, Manish, et al.
Publicado: (2021)

Type 2 Diabetic Patients Adherence Towards Their Medications
por: Alshehri, Khalid A, et al.
Publicado: (2020)

Multifocal C-cell Hyperplasia and Marked Hypercalcitoninemia in a Diabetic Patient Treated With Glucagon-Like Peptide-1 Agonist With Concurrent Multinodular Goiter and Hyperparathyroidism
por: Zou, Sifan, et al.
Publicado: (2023)

Fertility and Obstetric Outcomes of Assisted Reproductive Technology (ART) in Women With Adenomyosis Following Gonadotropin-Releasing Hormone Agonist Therapy: A Single-Center Experience
por: Rao, Asha R, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lagque5vunenvm0mb0ql8hlnfu